BDBM136699 US8865662, 3::US9738676, WS2011/018510, Expl. 2

SMILES CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C(=O)N2CCOCC2)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCOc3cc(ccc3OC)C(=O)Nc3c(Cl)cncc3Cl)C(=O)O[C@]12C)OC

InChI Key InChIKey=KQNZEFPYFFFLQN-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 136699   

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Human)
Basilea Pharmaceutica

US Patent
LigandPNGBDBM136699(US8865662, 3 | US9738676, WS2011/018510, Expl. 2)
Affinity DataIC50: 630nMpH: 7.2Assay Description:PDE4 specifically hydrolyzes cAMP and releases the product AMP. The potency of PDE inhibition by said agents is determined in an in vitro enzymatic a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2015
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Human)
Basilea Pharmaceutica

US Patent
LigandPNGBDBM136699(US8865662, 3 | US9738676, WS2011/018510, Expl. 2)
Affinity DataIC50: 876nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent